|Strain Name||C57BL/6-Ctla4tm1(hCTLA4)/Bcgen||Common Name||B-hCTLA4 mice|
|Catalog number (Males)||BCM024M||Catalog number (Females)||BCM024F|
|Related Genes||Ctla4 (cytotoxic T-lymphocyte-associated protein 4)|
CTLA4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152, competitively binds to B7-1 (CD80) and B7-2 (CD86) on Antigen-Presenting Cells (APCs) to block the T cell activating signal by B7 and CD28 (on T cells) interaction. The inhibition of CTLA4 by its inhibitory antibodies enhances T cell activity. The CTLA4 antibody is the first FDA-approved antibody to treat advanced melanoma.
mRNA expression verification
Fig 1. RT-PCR analysis of CTLA4 gene.
The hCTLA4, but not mCTLA4, mRNA was detected in splenocytes of the homozygous B-hCTLA4 mice.
Protein expression analysis
Fig 2. Spleen from both wild type (WT) C57BL/6 and the B-hCTLA4 homozygous mice were analyzed by flow cytometry.
Mouse CTLA4+ T cells were detected in the WT mice, while human CTLA4+ T cells were detected in the homozygous B-hCTLA4 mice.
CTLA4(Yervoy) Ab efficacy evaluation (different doses)
Fig 3. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hCTLA4 mice. Mice were divided into control and treatment groups (n=5) when the tumor size was approximately 100 mm3. Three doses of the anti-hCTLA4 antibody Yervoy differentially inhibited tumor growth in the homozygous B-hCTLA4 mice, suggesting that B-hCTLA4 mouse model is an effective tool for in vivo hCTLA4 antibody efficacy studies. The average±SEM of tumor sizes are shown in the figure. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.